| WAYNE STATE UNIVERSITY Patent applications |
| Patent application number | Title | Published |
|---|
| 20120133774 | AUTOMATED VIDEO SURVEILLANCE SYSTEMS - A video surveillance system includes a plurality of video sources, at least one processing server in communication with the video sources, and at least one monitoring station viewing video from the video sources. The video sources are distributed over a target area to be monitored by the surveillance system and are attached to a video network. The processing server allocates bandwidth to the video sources with an accuracy function which provides event/object detection accuracy as a function of image/video quality transferred over the network. The image accuracy is the accuracy with which the processing server identifies features in a video image. Bandwidth is allocated by optimizing the overall event/object detection accuracy by adjusting image/video quality for each video source optionally subject to the dynamic network conditions experienced by each video source. | 05-31-2012 |
| 20120121589 | MODIFIED EGFR ECTODOMAIN - A protein that attenuates EGFR and/or EGFR family members comprises a modified EGFR ectodomain. The protein inhibits signaling via the EGFR and/or EGFR family members. The protein includes a portion of the EGFR (or EGFR family member) and the “U” region epitope of EGFR related protein (ERRP), wherein the portion of the EGFR is operable to bind a ligand of EGFR. Also included are nucleic acids encoding such proteins. Attenuating EGFR signaling can include inhibiting the EGFR and/or EGFR family members and to provide antiproliferative activity. The present proteins and expression of nucleic acids encoding these proteins can regulate cellular growth and can be used to treat tumors and cancerous cells that express one or more of the EGFR and EGFR family members. | 05-17-2012 |
| 20120108815 | BIFUNCTIONAL/POLYFUNCTIONAL DOPAMINE D2/D3 AGONIST AS NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES - A precursor for the deposition of a thin film by atomic layer deposition is provided. The compound has the formula M | 05-03-2012 |
| 20120107828 | METHOD FOR IDENTIFYING A SUBPOPULATION OF MAMMALIAN CELLS WITH DISTINCTIVE RIBOSOME TRANSLATION PROFILES - The present invention generally relates to subpopulations of mammalian cells with distinctive ribosome translational profiles, i.e. translational activities. The present invention further relates to methods for identifying and isolating such cells, kits comprising the same, or methods which utilize different translational activities of these subpopulations of mammalian cells. | 05-03-2012 |
| 20120096631 | OMNI-DIRECTIONAL ANGULAR ACCERATION REDUCTION FOR PROTECTIVE HEADGEAR - Protective headgear includes an outer shell rotatable relative to an inner shell via a thin layer of elastically and/or plastically yielding material disposed between and secured to the inner and outer shells. The yielding material deforms continuously but non-linearly at least in the tangential or shear direction to mitigate angular acceleration of the head during an impact. The yielding material prevents the inner and outer shells from separating or stopping suddenly to avoid imparting a large angular acceleration to the head. In one embodiment, a protective helmet includes an outer shell secured to an inner shell by a yielding material that elastically deforms continuously but non-linearly when subjected to an angular acceleration below a first threshold and plastically deforms when subjected to an angular acceleration above the first threshold. | 04-26-2012 |
| 20120095117 | GALECTIN-3 nsSNP MARKER FOR CANCER - A diagnostic biomarker including a mechanism for determining a patient's propensity to develop cancer. A diagnostic kit for determining a patient's propensity to develop cancer. A method of predicting both a patient's and a population's propensity to develop cancer, by detecting the presence of an H | 04-19-2012 |
| 20120093718 | LIPOSOMAL NANOPARTICLES AND OTHER FORMULATIONS OF FENRETINIDE FOR USE IN THERAPY AND DRUG DELIVERY - Formulations of neutral retinoids, in particular fenretinide (HPR) in the form of lipid nanoparticles, solid dipersions and emulsions are disclosed. These compositions are used to treat diseases that are amenable to treatment by HPR, such as neoplastic diseases by achieving higher and more prolonged concentrations of HPR in the subject. The key steps for preparing lipid nanovesicles of HPR include mixing and sonication, sterile filtration, without or without lyophilization for long-term stable storage, and employ processes and materials that are scalable from the laboratory to the manufacturing level. The formulation are suitable for injection into human or animal patients without causing allergic or hypersensitivity responses by avoiding chemical surfactants and animal sources of phospholipids in their manufacture. | 04-19-2012 |
| 20120085903 | MASS SPECTOMETRY USING LASERSPRAY IONIZATION - Disclosed herein are systems and methods for mass spectrometry using laserspray ionization (LSI). LSI can create multiply-charged ions at atmospheric pressure for analysis and allows for analysis of high molecular weight molecules including molecules over | 04-12-2012 |
| 20120058270 | THERMALLY STABLE VOLATILE FILM PRECURSORS - A precursor for the deposition of a thin film by atomic layer deposition is provided. The compound has the formula MxLy where M is a metal and L is an amidrazone-derived ligand or an amidate-derived ligand. A process of forming a thin film using the precursors is also provided. | 03-08-2012 |
| 20120046182 | NEOEPITOPE DETECTION OF DISEASE USING PROTEIN ARRAYS - A biosensor for use in detecting the presence of diseases, the biosensor comprising a detector for detecting a presence of at least one marker indicative of a specific disease. A method of determining efficacy of a pharmaceutical for treating a disease or staging disease by administering a pharmaceutical to a sample containing markers for a disease, detecting the amount of at least one marker of the disease in the sample, and analyzing the amount of the marker in the sample, whereby the amount of marker correlates to pharmaceutical efficacy or disease stage. Markers for gynecological disease selected from the list in Table 8. An immuno-imaging agent comprising labeled antibodies, whereby the labeled antibodies are isolated and reactive to proteins overexpressed in vivo. Informatics software for analyzing the arrays of claim | 02-23-2012 |
| 20120028893 | Adenovirus 36 E4 ORF 1 Gene and Protein and Their Uses - Expression of the E4 orf 1 gene of Ad-36 alone has been discovered to be responsible for the increased insulin sensitivity observed in Ad-36 infected animals, including increased adipogenesis. Ad-36 E4 orf 1 protein can be used to increase insulin sensitivity and ameliorate diabetes. Additionally, drugs that mimic the action of Ad-36 E4 orf 1 protein could be found. Ad-36 E4 orf 1 could also be used to increase fat cells in lipodystrophy. We have also discovered that Ad-36 infection in human skeletal muscle cells increased differentiation and insulin independent glucose uptake. It is expected that infection with Ad-36 E4 orf 1 gene will also cause these effects. | 02-02-2012 |
| 20120004428 | Tri-Substituted 2-Benzhydryl-5-Benzylamino-Tetrahydro-Pyran-4-OL and 6-Benzhydryl-4-Benzylamino-Tetrahydro-Pyran-3-OL Analogues, and Novel 3,6-Disubstituted Pyran Derivatives - Novel 3,6-disubstituted pyrans, optionally with a further substituent at the 4-position, are monoamine reuptake inhibitors with activity profiles of anti-depressants. | 01-05-2012 |
| 20120003155 | DENDRIMER BASED NANODEVICES FOR THERAPEUTIC AND IMAGING PURPOSES - A nanodevice composition including N-acetyl cysteine linked to a dendrimer, such as a PAMAM dendrimer or a multiarm PEG polymer, is provided. Also provided is a nanodevice for targeted delivery of a compound to a location in need of treatment. The nanodevice includes a PAMAM dendrimer or multiarm PEG polymer, linked to the compound via a disulfide bond. There is provided a nanodevice composition for localizing and delivering therapeutically active agents, the nanodevice includes a PAMAM dendrimer or multiarm PEG polymer and at least one therapeutically active agent attached to the PAMAM dendrimer or multiarm PEG polymer. A method of site-specific delivery of a therapeutically active agent, by attaching a therapeutically active agent to a PAMAM dendrimer or multiarm PEG polymer using a disulfide bond, administering the PAMAM dendrimer or multiarm PEG polymer to a patient in need of treatment, localizing the dendrimer or multiarm PEG polymer to a site in need of treatment, and releasing the therapeutically active agent at the site in need of treatment. | 01-05-2012 |
| 20110236484 | Genus-Wide Chlamydial Peptide Vaccine Antigens - Peptides generated from a random library that are bound by a monoclonal antibody to Chlamydial glycolipid exoantigen (GLXA) and thus mimic this antigen are disclosed. Peptides that correspond to antigen-binding regions of an anti-idiotypic antibody (mAb2) specific for anti-GLXA antibody (Ab1) which act as molecular mimics of GLXA are also disclosed used as immunogens to induce broadly reactive genus-specific anti-chlamydial antibodies. These peptides and immunogenic DNA encoding the mAb2-like peptides, microparticle or nanoparticle formulations and other formulations of these peptides are disclosed as are methods for immunizing subjects to obtain genus-specific anti-chlamydial antibodies and to treat or prevent | 09-29-2011 |
| 20110224312 | ENGINEERING POROUS PARTICLES OF WATER SOLUBLE THERAPEUTICS FOR PRESSURIZED METERED-DOSE INHALER FORMULATIONS - The subject matter disclosed herein relates to methods for engineering porous particles of water soluble therapeutics with enhanced physical stability and aerosol characteristics in hydrofluoroalkane (HFA)-based pressurized metered-dose inhaler (pMDI) formulations. | 09-15-2011 |
| 20110224275 | INHIBITORS OF MATRIX METALLOPROTEINASES - The present invention provides novel compounds of formulas I-IX, as described herein. Also provided are compositions of compounds of formulas I-IX, methods of making compounds of formulas I-IX, and methods of using compounds of formulas I-IX. The compounds of the invention can be used to inhibit matrix metalloproteinases, and are useful to treat conditions and diseases associated therewith. | 09-15-2011 |
| 20110223216 | Nanoparticles and Porous Particles and Methods of Making the Same - The subject matter disclosed herein relates to compositions and methods for engineering porous particles for aerosol formulations for pulmonary drug delivery. Certain embodiments disclosed herein further relate to methods for stabilizing suspension-based formulations in hydrofluoroalkane propellants with nanoparticles. | 09-15-2011 |
| 20110212472 | Asbestos Exposure, Pleural Mesothelioma and Osteopontin Levels - The present invention provides diagnostic and disease progression or recurrence prediction methods based on osteopontin levels in a biological sample. | 09-01-2011 |
| 20110191874 | COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING CELL DEATH BY A TRANSLATION REGULATED GENE EXPRESSION SYSTEM - The technology relates to a nucleic acid expression cassette comprising a TR element encoding an mRNA molecule that is translated in stressed and/or dying cells, and a nucleotide sequence operably linked to the TR element, that is a first open reading frame (ORF) sequence and encodes a polypeptide or a fragment thereof and is co-translated with the TR element. The technology further relates to mammalian cells and a transgenic animal comprising such expression cassette. Further included are kits comprising the expression cassette, and methods for determining toxicity, and killing a target cell | 08-04-2011 |
| 20110152210 | POLYPHENOL COMPOUNDS FOR INHIBITING PROTEASOME AND USES THEREOF - Synthetic polyphenolic compounds of formula (I), their modes of synthesis, and pharmaceutical compositions thereof are provided herein. Use of the compounds and compositions described herein for inhibiting proteasomal activity and for treating cancer is also provided. | 06-23-2011 |
| 20110114233 | DEVELOPMENT OF A HIGH STRENGTH HIGH TOUGHNESS BAINITIC STEEL - A bainitic steel with simultaneous high yield strength and high fracture toughness includes at least 5 volume percent austenite as well as iron, carbon, and silicon. The silicon is present in an amount of at least 1.5 weight percent of total weight of the bainitic steel. A method of forming the steel by austempering is also provided. | 05-19-2011 |
| 20110034422 | DENDRIMERS FOR SUSTAINED RELEASE OF COMPOUNDS - Dendrimer-based compositions and methods are provided, that are useful for administering pharmaceutical compositions to target cells and tissues for treatment of ocular diseases including macular degeneration, diabetic retinopathy, and retinitis pigmentosa. | 02-10-2011 |
| 20110021748 | Non-Natural Peptides as Models for the Development of Antibiotics - Described herein are methods of screening one of the RNA hairpins in the small ribosomal subunit of bacteria to identify peptides that bind to it. The RNA hairpin target may be the 970 loop (aka helix 31 (h31)) or a modified version thereof. The identified peptides may inhibit protein synthesis and, therefore, may be used as a model for new antibiotics. | 01-27-2011 |
| 20110020849 | BIOMARKERS FOR DIAGNOSTIC AND THERAPEUTIC METHODS - Erythrocyte ATP-release modulators and composition and methods for their use as biomarkers of glucose processing or vascular disorders, as well as methods for screening to identify to modulators; methods for monitoring efficacy of therapy; and apparatus for use in such methods. | 01-27-2011 |
| 20110020471 | ERYTHROCYTE ATP-RELEASE MODULATORS - Erythrocyte ATP-release modulators and composition and methods for their use to potentiate serum glucose clearance and vasodilation; methods for prophylactic or palliative therapy of glucose processing or vascular disorders; processes for preparing the modulators and compositions comprising them; and kits therefor. | 01-27-2011 |
| 20110003897 | METHODS OF ENGINEERING POLAR DRUG PARTICLES WITH SURFACE-TRAPPED HYDROFLUOROALKANE-PHILES - Disclosed herein are polar drug particles with surface-trapped hydrofluoroalkane-philes and methods of making the same. | 01-06-2011 |
| 20110002930 | Activated T Cells - Provided are compositions comprising activated T cells and activated T cells armed with bispecific antibodies directed at cancer antigens which are poor responders to alloantigen, and methods of using the compositions to help engraftment and improve anti-tumor effects. | 01-06-2011 |
| 20100322871 | Co-polymer Stabilizers For Hydryfluoroalkane Dispersions - The use of biodegradable and biocompatible lactide-based nonionic amphiphiles to stabilize a model drug (salbutamol base) dispersion in hydrofluoroalkane (HFA) propellant is disclosed. The results have industrial applicability to the development of HFA-based dispersion pressurized metered-dose inhaler formulations. | 12-23-2010 |
| 20100280091 | TRI-SUBSTITUTED 2-BENZHYDRYL-5-BENZYLAMINO-TETRAHYDRO-PYRAN-4-OL AND 6-BENZHYDRYL-4-BENZYLAMINO-TETRAHYDRO-PYRAN-3-OL ANALOGUES, AND NOVEL 3,6-DISBUSTITUTED PYRAN DERIVATIVES - Novel 3,6-disubstituted pyrans, optionally with a further substituent at the 4-position, are monoamine reuptake inhibitors with activity profiles of anti-depressants. | 11-04-2010 |
| 20100273745 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS - Polyamine, polyamine/guanidino, and polyamine/biguanide compounds are disclosed. The compounds are useful as anti-cancer and anti-parasitic treatments. The compounds are also useful as inhibitors of the enzyme lysine-specific demethylase-1. | 10-28-2010 |
| 20100239765 | COMPOUNDS FOR FORMING METAL NITRIDES - Nitride forming precursors are heated to form a metal nitride on a substrate. In some variations, the precursors are contacted with the substrate which has previously been heated to a sufficient temperature to form a nitride film. Precursors to tungsten and molybdenum nitride are provided. | 09-23-2010 |
| 20100233700 | UBIAD1 GENE AND HYPERLIPIDEMIA - The disclosure relates to genetic mutations in UBIAD1 gene that segregate with Schnyder's crystalline corneal dystrophy. The disclosure provides methods for detecting such mutations as a diagnostic for Schnyder's crystalline corneal dystrophy either before or after the onset of clinical symptoms. Also provided are screening methods for identifying medical conditions related to cholesterol metabolism, including atherosclerosis, risk of future loss of vision, and future need for corneal transplantation. | 09-16-2010 |
| 20100210663 | Hybrid 2-Aminotetralin and Aryl-Substituted Piperazine Compounds and their Use in Altering CNS Activity - Hybrid compounds containing an aminotetralin moiety or a heterocyclic and/or open chain analog thereof linked through an alkylene group to an aryl ring system-substituted piperidiene moiety exhibit high levels of CNS activity, in some cases exhibiting especially high relative binding efficiencies between D3 and D2 dopaminergic receptor subtypes. | 08-19-2010 |
| 20100202969 | NANOPARTICLES FOR IMAGING AND TREATING CHLAMYDIAL INFECTION - Compositions of nanoparticles and targeting moieties for imaging and treating Chlamydial infection are provided, including nanoparticles conjugated to folic acid and comprising at least one antibiotic effective against | 08-12-2010 |
| 20100183875 | PARTICLE-ROD NANOSTRUCTURES - A particle-rod nanostructure is disclosed. The nanostructure comprises an inorganic nanoparticle coated with a capping agent and an organic crystalline rod nucleated on the capped inorganic nanoparticle in a one-dimensional growth pattern. | 07-22-2010 |
| 20100104516 | USE OF FLAGELLIN TO PREVENT AND TREAT GRAM NEGATIVE BACTERIAL INFECTION - The disclosure describes use of flagellin polypeptides to induce tolerance to gram negative bacteria, such as | 04-29-2010 |
| 20100098679 | PROMOTION OF PEROXISOMAL CATALASE FUNCTION IN CELLS - The molecular mechanisms of peroxisome biogenesis have begun to emerge; in contrast, relatively little is known about how the organelle functions as cells age. The present inventors characterized age-related changes in peroxisomes of human cells and showed that aging compromises peroxisomal targeting signal 1 (PTS1) protein import, with the critical antioxidant enzyme, catalase, especially affected. The number and appearance of peroxisomes are altered in these cells, and the organelles accumulate the PTS1-import receptor, Pex5p, on their membranes. Concomitantly, cells produce increasing amounts of the toxic metabolite, H | 04-22-2010 |
| 20100043881 | TITANIUM DIOXIDE THIN FILM SYSTEMS AND METHOD OF MAKING SAME - A method for producing a thin film titanium dioxide is disclosed. The disclosed method for producing the thin film titanium dioxide includes performing a magnetron reactive sputtering process to vaporize at least portions of a titanium source in a sputtering chamber that is supplied with gaseous oxygen. The vaporized titanium reacts with the oxygen to form anatase titanium dioxide, which is deposited on a substrate within the sputtering chamber. | 02-25-2010 |
| 20100037682 | BIOSENSOR BASED ON POLYMER CANTILEVERS - A microcantilever sensor includes a supporting substrate, a cantilever spring element at least partially disposed over the support substrate, a probe layer disposed over the first side of the cantilever spring element, and a piezoresistive transducer attached to the second side of the cantilever spring element. The cantilever spring element is characterized by having a first side and a second side and comprising a polymer having a Young's modulus less than about 100 Gpa. Sensing systems that incorporate the cantilever sensor of the invention include a detector in communication with the piezoresistive transducer to provide measurements of surface strain changes in the piezoresistive transducer. | 02-18-2010 |
| 20100028977 | ENCLOSED PHOTOBIOREACTORS WITH ADAPTIVE INTERNAL ILLUMINATION FOR THE CULTIVATION OF ALGAE - The present invention provides an enclosed, internally-lighted bioreactor apparatus, methods for growing photosynthetic microorganisms in the enclosed, internally lighted bioreactor and methods for enhancing growth of a photosynthetic microorganism culture in the enclosed internally-lighted bioreactor. | 02-04-2010 |
| 20100016600 | N- and O-Substituted 4-[2-(Diphenylmethoxy)-Ethyl]-1-[(Phenyl)Methyl]Piperdine Analogs and Methods of Treating CNS Disorders Therewith - N- and O-substituted 4[2-diaromaticmethoxy and methylamino)alkyl]piperidines exhibit high CNS activity with respect to the dopamine transporter (DAT) and serotonin transporter (SERT). Preferred compounds exhibit highly differential behavior as between the DAT and SERT and between the DAT and the norepinephrine transporter (NET). The compounds have utility in treating CNS disorders, including but not limited to cocaine addiction, depression, and Parkinson's disease. | 01-21-2010 |
| 20100015095 | RESTORATION OF VISUAL RESPONSES BY IN VIVO DELIVERY OF RHODOPSIN NUCLEIC ACIDS - Nucleic acid vectors encoding light-gated cation-selective membrane channels, in particular channelrhodopsin-2 (Chop2), converted inner retinal neurons to photosensitive cells in photoreceptor-degenerated retina in an animal model. Such treatment restored visual perception and various aspects of vision. A method of restoring light sensitivity to a retina of a subject suffering from vision loss due to photoreceptor degeneration, as in retinitis pigmentosa or macular degeneration, is provided. The method comprises delivering to the subject by intravitreal or subretinal injection, the above nucleic acid vector which comprises an open reading frame encoding a rhodopsin, to which is operatively linked a promoter and transcriptional regulatory sequences, so that the nucleic acid is expressed in inner retinal neurons. These cells, normally light-insensitive, are converted to a light-sensitive state and transmit visual information to the brain, compensating for the loss, and leading to restoration of various visual capabilities. | 01-21-2010 |
| 20100015050 | PEG AND TARGETING LIGANDS ON NANOPARTICLE SURFACE - Provided are compositions of nanoparticles, PEG and targeting moieties. The compositions are useful in treating tumors, imaging the particles in tissues, and in targeting therapeutic agents to specific tissues and locations in a patient. Also provided are methods of preparing and methods of using the compositions. | 01-21-2010 |
| 20090311721 | ASBESTOS EXPOSURE, PLEURAL MESOTHELIOMA, AND SERUM OSTEOPONTIN LEVELS - The present invention provides diagnostic methods based on the serum levels of osteopontin. | 12-17-2009 |
| 20090298111 | METHOD AND COMPOSITION FOR A PROTEIN TRANSDUCTION TECHNOLOGY AND ITS APPLICATIONS - A protein transduction method for efficiently delivery of exogenous proteins into mammalian cells is invented, which has the capability of targeting different cellular compartments and protection from degradation of the delivered proteins from cellular proteases. A composition for treat proteins has cation reagents, lipids and enhancers in a carrier. The method can be used in a number of ways including: production of large quantities of properly folded, post-translationally modified proteins using mammalian cell machinery, a in-cell fluorescence spectroscopy and imaging using small molecule fluorophores and a in-cell NMR spectroscopy using living mammalian cells. The method permits cell biology at atomic resolution that is physiologically and pathological relevant and permits protein therapy to treat human diseases. The method can also be used to deliver exogenous protein inside mammalian cells, wherein the exogenous proteins follow a similar secretion pathway as that of the endogenous protein. | 12-03-2009 |
| 20090269779 | Galectin-3 cleavage as a marker for matrix metalloproteinase activity in cancer - Provided are differential antibodies recognizing the cleaved and non-cleaved forms of matrix metalloproteinases (MMPs), and methods of using the antibodies as surrogate diagnostic markers for the presence of active MMPs in cancer, such as growing breast cancers. | 10-29-2009 |
| 20090232648 | REDUCTION OF FLOW-INDUCED NOISE IN A CENTRIFUGAL BLOWER - A centrifugal blowing apparatus for reducing flow-induced noise is disclosed. The apparatus includes a blower housing having a scroll section formed about a rotational axis and an exhaust section extending from the scroll section. The scroll section includes an opening defining an inlet configured to draw in air and the exhaust section defines an outlet in fluid communication with the inlet. The scroll section commences with a reduced cross-sectional area defining a cutoff and expands to an increased cross-sectional area. An impeller is disposed in the opening of the scroll section about the rotational axis and comprises an outer surface having impeller blades radially disposed thereon. The impeller blades rotate to direct a flow of air from the inlet through the scroll section to the outlet. A plurality of indentations is formed along an inner surface of the scroll section at the cutoff. | 09-17-2009 |
| 20090214590 | Virus Vaccines Comprising Envelope-Bound Immunomodulatory Proteins and Methods of Use Thereof - The present invention provides novel virus vaccines with augmented, e.g., enhanced and/or extended immunogenicity. The virus vaccines of the invention comprise an envelope-bound immunomodulatory protein, e.g., a cytokine, chemokine or costimulatory molecule. The immunomodulatory protein serves as an adjuvant to augment, e.g., enhance or extend the immunogenicity of the virus vaccine, thereby augmenting, e.g., enhancing or extending immune response to the virus when administered to a subject. | 08-27-2009 |
| 20090188576 | CHECK VALVE DIAPHRAGM MICROPUMP - A micropump device including a first wafer and a second wafer attached to the first wafer. The first and second wafers are configured to define a chamber therebetween having a predetermined volume. A third wafer is attached to the second wafer to define an inlet section and an outlet section in fluid communication with the chamber. At least one of the second and third wafers are formed to define a moveable diaphragm configured to change the predetermined volume of the chamber for pumping a fluid between the inlet section and the outlet section. | 07-30-2009 |
| 20090182019 | Histone deacetylase inhibitors - The present invention provides novel HDAC inhibitors and methods of treating diseases using the same. | 07-16-2009 |
| 20090173700 | DEVICE AND METHOD OF SEPARATING AND CONCENTRATING MICROFLUIDIC PARTICLES - A flow unit for microfluidic particles separation and concentration is disclosed. The unit comprises a nozzle segment, a turn segment, and a diffuser segment. The nozzle segment is defined by a first member and a second member, and has an opening through which fluid and microfluidic particles enter. The nozzle segment has a narrowing portion at which the first and second members narrow from the opening to increase momentum of the fluid therethrough. The turn segment is defined by the first member flaring outwardly downstream from the narrowing portion to change flow direction of the fluid consistent with the first member. The diffuser segment is defined by the second member extending past the turn segment to facilitate separation of the microfluidic particles from the fluid due to the inability to follow the fluid flow. | 07-09-2009 |
| 20090142936 | METHOD OF FORMING GATED, SELF-ALIGNED MICRO-STRUCTURES AND NANO-STRUCTURES - Methods of forming a gated, self-aligned nano-structures for electron extraction are disclosed. One method of forming the nano-structure comprises irradiating a first surface of a thermally conductive laminate to melt an area across the first surface of the laminate. The laminate comprises a thermally conductive film and a patterned layer disposed on the first surface of the film. The patterned layer has a pattern formed therethrough, defining the area for melting. The film is insulated at a second surface thereof to provide two-dimensional heat transfer laterally in plane of the film. The liquid density of the film is greater than the solid density thereof. The method further comprises cooling the area inwardly from the periphery thereof to form the nano-structure having an apical nano-tip for electron emission centered in an electrically isolated aperture that serves as a gate electrode to control electron extraction in a gated field emitter device. | 06-04-2009 |
| 20090118308 | 2,2-Bis-(hydroxymethyl)cyclopropylidenemethyl-Purines and -Pyrimidines As Antiviral Agents - Compounds which are active against viruses have the following formulas: | 05-07-2009 |
| 20090035310 | CANCER TREATMENT - Pharmaceutical compositions and methods for inhibiting tumor growth and/or for inducing apoptosis are provided. Such compositions comprise at least one polypeptide of contiguous amino acids 1-198, 197-454, or 896-1150 of CARP-1 protein, and derivatives thereof, and may optionally comprise one or more cancer chemotherapeutic agents. Also provided are plasmids encoding the polypeptides, and methods of using the polypeptides and plasmids to inhibit cancer cell growth, including in mammals. | 02-05-2009 |
| 20080227707 | BIOACTIVE PEPTIDES AND UNIQUE IRES ELEMENTS FROM MYELIN PROTEOLIPID PROTEIN PLP/DM20 - Three novel low molecular weight (LMW) polypeptide fragments of a proteolipid protein human PLP/DM20 are designated PIRP-M, PIRP-L and PIRP-J, and are growth factors for oligodendrocytes with anti-apoptotic activity. They are encoded by mRNA from an IRES. Fusion polypeptides of such a LMW polypeptide, DNA encoding the LMW polypeptide and fusion polypeptide, expression vectors comprising such DNA, and cells expressing such polypeptides, or pharmaceutical compositions thereof, are useful for stimulating neural stem cell differentiation, maturation along the oligodendrocytic pathway and proliferation of oligodendrocytes or precursors. These compositions can protect oligodendrocytes (and nonneural cells) from apoptotic death. Thus, the present composition is used to treat a disease or condition in which such differentiation, maturation and proliferation or inhibition of cell death, including remyelination or stimulation of oligodendroglia or Schwann cells, is desirable. Disorders include multiple sclerosis, trauma with Parkinson's-like symptoms, hypoxic ischerriia and spinal cord trauma. | 09-18-2008 |
| 20080199659 | TRANSPARENT HYDROPHOBIC ARTICLE HAVING SELF-CLEANING AND LIQUID REPELLANT FEATURES AND METHOD OF FABRICATING SAME - A transparent hydrophobic article having self-cleaning and liquid repellent features is disclosed. The article comprises a transparent substrate comprising a subwavelength structured surface including arrays of protuberances. Each protuberance has a predetermined distance to its adjacent neighbor and a predetermined height to minimize light diffraction and random scattering therethrough. The article further comprises a hydrophobic material disposed on the subwavelength structured surface. The hydrophobic material has a predetermined thickness and a predetermined hydrophobicity for self-cleaning and repelling from fluids thereon. | 08-21-2008 |
